0002019886-24-000019.txt : 20240521 0002019886-24-000019.hdr.sgml : 20240521 20240521160335 ACCESSION NUMBER: 0002019886-24-000019 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b ITEM INFORMATION: Investment Company Act Section 3(c) ITEM INFORMATION: Section 3(c)(1) FILED AS OF DATE: 20240521 DATE AS OF CHANGE: 20240521 EFFECTIVENESS DATE: 20240521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solas BioVentures Emerging Healthcare Fund, LP CENTRAL INDEX KEY: 0001940916 ORGANIZATION NAME: IRS NUMBER: 883266786 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-463813 FILM NUMBER: 24969239 BUSINESS ADDRESS: STREET 1: 412 GEORGIA AVENUE STREET 2: SUITE 201 CITY: CHATTANOOGA STATE: TN ZIP: 37403 BUSINESS PHONE: (423) 243-3460 MAIL ADDRESS: STREET 1: 412 GEORGIA AVENUE STREET 2: SUITE 201 CITY: CHATTANOOGA STATE: TN ZIP: 37403 D/A 1 primary_doc.xml X0708 D/A LIVE 0001940916 Solas BioVentures Emerging Healthcare Fund, LP 412 GEORGIA AVENUE SUITE 201 CHATTANOOGA TN TENNESSEE 37403 (423) 243-3460 DELAWARE None None Limited Partnership true 2022 David Belitz 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Executive Officer Promoter Manager of the Investment Manager of the Issuer. Mark D. Hackett 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Executive Officer Promoter Manager of the Investment Manager of the Issuer. David C. Adair 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Executive Officer Promoter Manager of the Investment Manager of the Issuer. n/a n/a Solas BioVentures Emerging Healthcare GP, LLC 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Promoter General Partner of the Issuer. n/a n/a Solas BioVentures Management, LLC 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Promoter Investment Manager of the Issuer. Pooled Investment Fund Other Investment Fund false Decline to Disclose 06b 3C 3C.1 true 0001973222-23-000004 2022-10-21 true true false 1000000 Indefinite 35150000 Indefinite false 26 0 true 0 true 150000 true Organizational Expenses will be reimbursed to the General Partner and Investment Manager. A management fee will paid to the Investment Manager in accordance with the Issuer's offering documents. false Solas BioVentures Emerging Healthcare Fund, LP Mark D. Hackett Mark D. Hackett Manager 2024-05-21